PHOTOCURE ASA NOK0.50PHOTOCURE ASA NOK0.50PHOTOCURE ASA NOK0.50

PHOTOCURE ASA NOK0.50

No trades
See on Supercharts

0IMT fundamentals

Key facts

Market capitalization
Founded
CEO
Website
About

Photocure ASA engages in the development and commercialization of pharmaceutical products based on photodynamic technology. Its products include Metvix for nonmelanoma skin cancer, Hexvix/Cysview for better detection and management of bladder cancer, and Cevira which is a photodynamic drug-device combination product for non-surgical treatment of high-grade cervical dysplasia. The company operates through the Commercial Franchise and Development Portfolio segments. The Commercial Franchise segment includes the sale of Hexvix/Cysview in the U.S. and Europe and other sales from partners and other products. The Development Portfolio segment focuses on the development of pipeline products. The company was founded in 1997 and is headquartered in Oslo, Norway.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

0IMT does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company